Clinical Trial Update: Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating irinotecan plus panitumumab as third-line therapy for metastatic colorectal cancer in KRAS wild-type patients; trial completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Vectibix (panitumumab)

Snippet

Sponsor: Vejle Hospital | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED